Literature DB >> 22860167

Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.

Douglas J Sheffler1, Anthony B Pinkerton, Russell Dahl, Athina Markou, Nicholas D P Cosford.   

Abstract

Group II metabotropic glutamate (mGlu) receptors consist of the metabotropic glutamate 2 (mGlu(2)) and metabotropic glutamate 3 (mGlu(3)) receptor subtypes which modulate glutamate transmission by second messenger activation to negatively regulate the activity of adenylyl cyclase. Excessive accumulation of glutamate in the perisynaptic extracellular region triggers mGlu(2) and mGlu(3) receptors to inhibit further release of glutamate. There is growing evidence that the modulation of glutamatergic neurotransmission by small molecule modulators of Group II mGlu receptors has significant potential for the treatment of several neuropsychiatric and neurodegenerative diseases. This review provides an overview of recent progress on the synthesis and pharmacological characterization of positive and negative allosteric modulators of the Group II mGlu receptors.

Entities:  

Keywords:  allosteric modulators; anxiety; drug dependence; mGlu2; mGlu3; memory; schizophrenia; sleep-wake architecture

Mesh:

Substances:

Year:  2011        PMID: 22860167      PMCID: PMC3369751          DOI: 10.1021/cn200008d

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  78 in total

1.  Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors.

Authors:  F Ferraguti; B Baldani-Guerra; M Corsi; S Nakanishi; C Corti
Journal:  Eur J Neurosci       Date:  1999-06       Impact factor: 3.386

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Stress-induced hyperthermia in singly housed mice.

Authors:  J A Van der Heyden; T J Zethof; B Olivier
Journal:  Physiol Behav       Date:  1997-09

Review 4.  Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2).

Authors:  Michael T Rudd; John A McCauley
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

5.  The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.

Authors:  J Cartmell; J A Monn; D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

6.  Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence.

Authors:  Matthias E Liechti; Loic Lhuillier; Klemens Kaupmann; Athina Markou
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

7.  3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators.

Authors:  Lei Zhang; Bruce N Rogers; Allen J Duplantier; Stanley F McHardy; Ivan Efremov; Helen Berke; Weimin Qian; Andy Q Zhang; Noha Maklad; John Candler; Angela C Doran; John T Lazzaro; Alan H Ganong
Journal:  Bioorg Med Chem Lett       Date:  2008-09-10       Impact factor: 2.823

8.  Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor.

Authors:  Anthony B Pinkerton; Jean-Michel Vernier; Hervé Schaffhauser; Blake A Rowe; Una C Campbell; Dana E Rodriguez; Daniel S Lorrain; Christopher S Baccei; Lorrie P Daggett; Linda J Bristow
Journal:  J Med Chem       Date:  2004-08-26       Impact factor: 7.446

9.  Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site.

Authors:  Blake A Rowe; Hervé Schaffhauser; Sylvia Morales; Laura S Lubbers; Celine Bonnefous; Theodore M Kamenecka; Jeffrey McQuiston; Lorrie P Daggett
Journal:  J Pharmacol Exp Ther       Date:  2008-04-22       Impact factor: 4.030

10.  A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.

Authors:  Michael A Benneyworth; Zixiu Xiang; Randy L Smith; Efrain E Garcia; P Jeffrey Conn; Elaine Sanders-Bush
Journal:  Mol Pharmacol       Date:  2007-05-25       Impact factor: 4.436

View more
  19 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats.

Authors:  Xia Li; Manoranjan S D'Souza; Ana M Niño; James Doherty; Alan Cross; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2016-02-13       Impact factor: 4.530

Review 3.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

Review 4.  Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  Darren W Engers; Craig W Lindsley
Journal:  Drug Discov Today Technol       Date:  2013

5.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

6.  Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu(2)/mGlu(3) NAMs.

Authors:  Cody J Wenthur; Ryan D Morrison; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2014-04-20       Impact factor: 2.823

7.  A Combination of Flow and Batch Mode Processes for the Efficient Preparation of mGlu2/3 Receptor Negative Allosteric Modulators (NAMs).

Authors:  Raveendra Panickar Dhanya; Ananda Herath; Douglas J Sheffler; Nicholas D P Cosford
Journal:  Tetrahedron       Date:  2018-03-30       Impact factor: 2.457

8.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).

Authors:  Cody J Wenthur; Ryan Morrison; Andrew S Felts; Katrina A Smith; Julie L Engers; Frank W Byers; J Scott Daniels; Kyle A Emmitte; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

9.  Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.

Authors:  Shyama Sidique; Raveendra-Panickar Dhanya; Douglas J Sheffler; Hilary Highfield Nickols; Li Yang; Russell Dahl; Arianna Mangravita-Novo; Layton H Smith; Manoranjan S D'Souza; Svetlana Semenova; P Jeffrey Conn; Athina Markou; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2012-10-23       Impact factor: 7.446

Review 10.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors:  Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.